IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients

A M Kucherenko; V M Pampukha; K Yu Romanchuk; S Yu Chernushyn; I A Bobrova; L V Moroz; L A Livshits

doi:10.3103/S0095452716050066

IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients

Cytol Genet. 2016;50(5):330-333. doi: 10.3103/S0095452716050066. Epub 2016 Oct 11.

Authors

A M Kucherenko¹, V M Pampukha¹, K Yu Romanchuk², S Yu Chernushyn¹, I A Bobrova³, L V Moroz², L A Livshits¹

Affiliations

¹ 1Department of Human Genomics, Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine, 150 Zabolotnogo str., 03680 Kyiv, Ukraine.
² 2Department of Infectious Diseases with Epidemiology Course, National Pirogov Memorial Medical University, 56 Pyrogova str., 21018 Vinnytsya, Ukraine.
³ Ukrainian Treatment and Diagnostic Center, 6D Mykilsko-Slobidska Str., 02002 Kyiv, Ukraine.

Abstract

The aim of this study was to examine association between IFNL4 gene ss469415590 and treatment efficiency in group of Ukrainian PEG-interferon/ribavirin-treated chronic hepatitis C patients. Study group consisted of 92 unrelated hepatitis C virus genotype 1 mono-infected patients: case group-29 patients with late or absent virological response; control group-63 patients with sustained virological response. Study material was genomic DNA. Genotyping was performed using amplification-refractory mutation system PCR. Statistical analysis was performed using GenePop and OpenEpi statistical packages. Obtained results show that ss469415590 ΔG/ΔG genotype is associated with poor virological response (OR = 3.62; CI 95%: 1.12-11.67) in PEG-interferon/ribavirin-treated chronic hepatitis C patients from Ukraine.

Keywords: IFNL4; hepatitis C; pharmacogenetic marker; treatment efficiency.